Perampanel Oral Suspension in the Treatment of Young Children with Epilepsy: A Multicenter Prospective Observational Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109538

Enrollment

Unknown

Registered

2025-09-19

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Perampanel (perampanel oral suspension adjunctive treatment):None

Eligibility

Sex/Gender

All

Age

1 Months to 4 Years

Inclusion criteria

Inclusion criteria: 1. Age between 1 month and 4 years old, male or female; 2. Diagnosed according to the 2017 International League Against Epilepsy (ILAE) classification criteria for Seizures and Epilepsy It was diagnosed as epilepsy. 3. At least one seizure in the 3 months before the visit; 4. Clinicians determined that perampanel oral suspension adjunctive treatment is suitable.

Exclusion criteria

Exclusion criteria: 1. Known to be allergic to the active ingredient of perampanel and the excipients of the oral suspension; 2. Participating in other clinical trials; 3. The investigator thought that the follow-up could not be completed on time.

Design outcomes

Primary

Measure	Time frame
50% responder rate;	—

Countries

China

Contacts

Public ContactYuwu Jiang

Peking University First Hospital

jiangyuwu@bjmu.edu.cn+86 176 3984 3553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026